Clinical Trial Update: Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial assessing metabolic effects of empagliflozin in patients with diabetic nephropathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Singapore General Hospital | Conditions: Diabetic Nephropathies | Phase 3 | Status: TERMINATED